Research programme: cyclo-oxygenase-2 inhibitors - Almirall Prodesfarma

Drug Profile

Research programme: cyclo-oxygenase-2 inhibitors - Almirall Prodesfarma

Latest Information Update: 22 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Almirall-Prodesfarma
  • Developer Almirall S.A
  • Class Pyrans; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatic disorders

Most Recent Events

  • 18 Aug 2004 This programme is still in active development
  • 19 Sep 2002 Preclinical trials in Rheumatic disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top